Columbia Asset Management Has Cut By $1.52 Million Its Dow Chemical Company (DOW) Stake; Adamis Pharmaceuticals (ADMP) Shorts Raised By 9.71%

May 23, 2017 - By Henry Gaston

Columbia Asset Management decreased Dow Chemical Company (DOW) stake by 13.3% reported in 2016Q4 SEC filing. Columbia Asset Management sold 26,717 shares as Dow Chemical Company (DOW)’s stock rose 0.05%. The Columbia Asset Management holds 174,218 shares with $9.97 million value, down from 200,935 last quarter. Dow Chemical Company now has $74.12B valuation. It closed at $60.98 lastly. It is down 20.72% since May 23, 2016 and is uptrending. It has outperformed by 4.02% the S&P500.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) had an increase of 9.71% in short interest. ADMP’s SI was 2.93M shares in May as released by FINRA. Its up 9.71% from 2.67M shares previously. With 876,500 avg volume, 3 days are for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)’s short sellers to cover ADMP’s short positions. The SI to Adamis Pharmaceuticals Corporation’s float is 17.42%. It closed at $3.95 lastly. It is down 52.09% since May 23, 2016 and is downtrending. It has underperformed by 68.79% the S&P500.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The company has market cap of $110.27 million. The Firm is engaged in the development of its specialty pharmaceutical products. It currently has negative earnings. The Firm is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company .

Among 2 analysts covering Adamis Pharma (NASDAQ:ADMP), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma had 3 analyst reports since December 1, 2015 according to SRatingsIntel. On Tuesday, December 1 the stock rating was initiated by Maxim Group with “Buy”. Maxim Group maintained the stock with “Buy” rating in Thursday, July 21 report.

Analysts await Dow Chemical Co (NYSE:DOW) to report earnings on July, 27. They expect $1.04 EPS, up 9.47% or $0.09 from last year’s $0.95 per share. DOW’s profit will be $1.26 billion for 14.66 P/E if the $1.04 EPS becomes a reality. After $1.04 actual EPS reported by Dow Chemical Co for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Investors sentiment increased to 1.52 in 2016 Q4. Its up 0.18, from 1.34 in 2016Q3. It is positive, as 53 investors sold DOW shares while 333 reduced holdings. 128 funds opened positions while 459 raised stakes. 790.77 million shares or 7.17% more from 737.86 million shares in 2016Q3 were reported. 44,578 were reported by Bb&T Corporation. Gp Inc One Trading Ltd Partnership reported 0% stake. Alliancebernstein L P, a New York-based fund reported 6.94 million shares. Dimensional Fund Advsrs Ltd Partnership reported 4.09M shares. Private Wealth Prns Limited Liability Co reported 0.39% stake. Neville Rodie And Shaw holds 0.14% of its portfolio in Dow Chemical Co (NYSE:DOW) for 20,880 shares. Mraz Amerine & Associate stated it has 0.13% in Dow Chemical Co (NYSE:DOW). Wesbanco Bankshares holds 0.7% or 215,748 shares in its portfolio. Moreover, Fagan Associate Inc has 1.78% invested in Dow Chemical Co (NYSE:DOW) for 53,795 shares. Louisiana State Employees Retirement holds 0.21% in Dow Chemical Co (NYSE:DOW) or 70,500 shares. Leavell Inc has 57,689 shares. Tci Wealth Advsr Inc has 0.2% invested in Dow Chemical Co (NYSE:DOW). Smith Salley Assocs owns 71,155 shares. Interocean Cap Ltd owns 1.26% invested in Dow Chemical Co (NYSE:DOW) for 102,987 shares. Investec Asset Mngmt North America Inc owns 31,160 shares.